drugset / Trial / NCT04896164

Randomized Trial of Curcumin to Reduce Mucositis in Autologous Transplant Setting

NCT04896164

Phase 3 Unknown 190 enrolled Tata Memorial Centre
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

Mucositis is a very common complication in bone marrow transplant setting. It is a result of injury to the gut caused by high dose chemotherapy. Currently there are no universal protocols that have been accepted as a standard to prevent and treat mucositis in the transplant setting. Post transplant upto 80% of patients suffer from a severe mucositis. Proinflammatory cytokines play a major role in the development of mucositis. Interventions that decrease the levels of these cytokines may be beneficial in preventing mucositis. This study is aimed at evaluating the role of curcumin in reducing cytokine levels and the incidence and duration of mucositis in patients undergoing autologous stem cell transplantation.

Timeline

Start
2018-12-16
Primary completion
2025-05-16
Completion
2025-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Curcumin Small molecule 400 mg Oral